Showing 1 - 6 results of 6 for search 'Meryl Darlington', query time: 0.03s Refine Results
  1. 1
    How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example

    How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example by Julie Bulsei, Meryl Darlington, Isabelle Durand-Zaleski, Michel Azizi, The DENERHTN Study Group

    Published 2018-03-01
    Get full text
    Article
  2. 2
    Decrementally cost-effective health technologies in non-inferiority studies: A systematic review

    Decrementally cost-effective health technologies in non-inferiority studies: A systematic review by Meryl Darlington, Raffaele Scarica, Xyomara Chavez-Pacheco, Laeticia Blamplain Segar, Isabelle Durand-Zaleski, Isabelle Durand-Zaleski

    Published 2022-12-01
    Get full text
    Article
  3. 3
    Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease

    Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease by Maroua Mimouni, Julie Bulsei, Meryl Darlington, Candice Estellat, François Rouzet, Fabien Hyafil, Isabelle Durand-Zaleski, the RUBIS Trial Group

    Published 2023-02-01
    Get full text
    Article
  4. 4
    Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?

    Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? by Jean-Michel Cayuela, Elizabeth Macintyre, Meryl Darlington, Raouf Ben Abdelali, Xavier Fund, Patrick Villarese, Michel Tulliez, Emmanuel Raffoux, François Sigaux, Delphine Réa, Valerie Seror

    Published 2011-05-01
    Get full text
    Article
  5. 5
    Cost-effectiveness of modified diagnostic strategy to safely rule-out pulmonary embolism in the emergency department: a non-inferiority cluster crossover randomized trial (MODIGLIA-NI)

    Cost-effectiveness of modified diagnostic strategy to safely rule-out pulmonary embolism in the emergency department: a non-inferiority cluster crossover randomized trial (MODIGLIA... by Arnaud Nze Ossima, Bibi Fabiola Ngaleu Siaha, Maroua Mimouni, Nadia Mezaour, Meryl Darlington, Laurence Berard, Marine Cachanado, Tabassome Simon, Yonathan Freund, Isabelle Durand-Zaleski

    Published 2023-11-01
    Get full text
    Article
  6. 6
    Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France

    Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France by Meryl Darlington, Pierre Sujobert, Olivier Kosmider, Damien Luque Paz, Sophie Kaltenbach, Martin Figeac, Sandrine Hayette, Nadia Mezaour, Séverine Coquerelle, Anne-Sophie Alary, Audrey Bidet, Yannick Le Bris, Eric Delabesse, Frédéric Davi, Claude Preudhomme, Isabelle Durand-Zaleski, Elizabeth Macintyre, Mélissa Alame, Fanny Baran-Marzak, Marc G. Berger, Dominique Bories, Aurélie Caye-Eude, Jean-Michel Cayuela, Pascale Cornillet-Lefebvre, François Delhommeau, Marie-Hélène Estienne-Felix, Pascaline Etancelin, Pascale Flandrin-Gresta, Eric Lippert, Christophe Marzac, Laurent Miguet, Cédric Pastoret, Sophie Raynaud, David Rizzo

    Published 2023-09-01
    Get full text
    Article

Search Tools: